Patients were matched for factors associated with HCC recurrence and survival.
依据与HCC复发和生存有关的因素对病人进行筛选。
In the Cox proportional hazards model, waitlist time was also not a significant predictor of HCC recurrence.
在Cox比例危险率模型中，等待时间也不是肝细胞癌复发的显著预测因子。
In addition, what other factors can be indicators of HCC recurrence after LT for HCC undergoing downstaging therapy?
除此外，还有哪些可能因素是预测经降级治疗后行肝移植HCC患者复发的指标？
CONCLUSIONS: We developed a composite prognostic model for HCC recurrence, based on gene expression patterns in tumor and adjacent tissues.
结论：根据肿瘤及其邻近组织的基因表达特征，我们建立了一个HCC复发的复合预后模型。
This paper is original since the authors evaluated several published molecular signatures of tumoral and non-tumoral tissue on HCC recurrence.
其具有创新性，因为作者对报导的与HCC复发相关的肿瘤和非肿瘤组织分子标记进行了评价。
For small HCC, in your opinion, should we choose to do hepatic resection, and then do salvage liver transplantation when HCC recurrence occurs, or directly do liver transplantation?
对于小肝癌，在您看来，我们应选择先做肝切除，然后当肝癌复发时再行肝移植术，还是直接行肝移植手术？
For small HCC, in your opinion, should we choose to do hepatic resection, and then do salvage liver transplantation when HCC recurrence occurs, or directly do liver transplantation?
对小肝癌，在你看来，咱们应抉择先做肝切除，而后当肝癌复发时再行肝移植术，仍是直接行肝移植手术？
Hepatocelluar carcinoma (HCC) is one of the most common human cancers worldwide, and metastatic recurrence is the major obstacle to improve the prognosis of HCC patients.
肝细胞癌是最常见的肿瘤之一，而转移复发则成为提高肝癌病人预后的主要障碍。
Conclusion Serum level of SIL-2R is of great value for early diagnosis, judgment of disease progress and monitoring of recurrence in patients with HCC.
结论血清SIL - 2 R水平可作为HCC病人早期诊断、病情判断、复发监测的重要指标。
To investigate effect of postoperative prophylactic transcatheter arterial chemoembolization(TACE)on delaying recurrence in patients with hepatocellular carcinoma(HCC).
了解预防性肝动脉化疗栓塞术（TACE）在延缓肝癌手术后复发方面的作用。
Although surgery is thus far the most efficient treatment for HCC, recurrence and metastasis of cancer cells after removal of cancer tumor or transplantation of liver may result in bad prognosis.
手术治疗仍然是目前肝癌最有效的治疗方法，但肝癌切除术或肝移植术后肿瘤的复发和转移是肝癌病人预后差的主要原因。
AIM: to investigate the prognostic value of biomarkers on predicting recurrence of hepatocellular carcinoma (HCC) after orthotopic liver transplantation (OLT).
目的：探讨生物学标记物对预测肝癌移植术后复发的价值。
CONCLUSION: CIK cell transfusion after micro-invasive treatments may improve the immunologic function in HCC patients, and play an important role in reducing the recurrence rate of HCC.
结论：微创治疗后联合cik细胞免疫治疗可提高肝癌患者的免疫功能，对降低肝癌的复发率具有重要作用。
Therefore, the most important factor is to select HCC patients for transplant that are low risk for recurrence.
因此，最重要的是选择复发风险低的HCC患者行肝移植术。
Potentially curable higher-stage HCC patients are denied LT due to the lack of cancer markers that predict progression and recurrence.
由于缺乏预测进展和复发的肿瘤标志物那些有可能被治疗的更高阶段的肝细胞癌的患者被拒绝用肝移植疗法。
Objective to explore the method of preventing and treating hepatocellular carcinoma (HCC) recurrence after surgical resection.
目的：探讨肝癌术后复发的防治方法。
The characteristic of HCC which is abundant with blood supply and easy to metastasis and recurrence suggests that angiogenesis plays a crucial role in tumorigenesis.
肝癌是富血管性肿瘤，其高血供、高转移、高复发的特点提示血管生成在肝癌的恶性生物学行为中扮演着十分重要的角色。
ABSTRACT: Objective to observe the precise time of the recurrence after resection of hepatocellular carcinoma (HCC) and to further explore the risk factors associated with postoperative recurrence.
摘要：目的观察肝细胞肝癌(HCC)患者术后准确的复发时间，进一步探讨影响肝癌术后复发的危险因素。
SIPA1 probably inhibits the metastasis and recurrence of HCC as a tumor suppressor gene.
SIPA1在HCC中发挥肿瘤抑制基因的作用，且对抑制HCC的复发转移有重要作用。
Conclusions This study suggests that tumor recurrence decreases and tumor free survival increases by adjuvant individualized chemotherapy after liver transplantation for HCC.
结论肝移植术后辅助个体化化疗能显著降低肝癌肝移植术后的肿瘤复发率 ，明显延长肝移植术后的无瘤生存时间。
Based on these signatures, they developed a composite risk score of recurrence of HCC after surgical resection and a composite score of poor survival after surgical resection.
依据这些标记，建立了HCC术后切除复合风险评估量表以及不良生存评估量表。
Based on these signatures, they developed a composite risk score of recurrence of HCC after surgical resection and a composite score of poor survival after surgical resection.
依据这些标记，建立了HCC术后切除复合风险评估量表以及不良生存评估量表。
应用推荐